Phase 1 Multiple Ascending Dose Study of BMS-907351 (XL184) Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To establish the MTD and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors
Within the first 28 days
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Japan: Pharmaceuticals and Medical Devices Agency
CA205-001
NCT01018745
January 2010
July 2010
Name | Location |
---|